Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 25.8 EUR -1% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Galapagos NV?
Write Note

Intrinsic Value

The intrinsic value of one GLPG stock under the Base Case scenario is 28.46 EUR. Compared to the current market price of 25.8 EUR, Galapagos NV is Undervalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLPG Intrinsic Value
28.46 EUR
Undervaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Galapagos NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GLPG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GLPG?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Galapagos NV

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Galapagos NV

Provide an overview of the primary business activities
of Galapagos NV.

What unique competitive advantages
does Galapagos NV hold over its rivals?

What risks and challenges
does Galapagos NV face in the near future?

Summarize the latest earnings call
of Galapagos NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Galapagos NV.

Provide P/S
for Galapagos NV.

Provide P/E
for Galapagos NV.

Provide P/OCF
for Galapagos NV.

Provide P/FCFE
for Galapagos NV.

Provide P/B
for Galapagos NV.

Provide EV/S
for Galapagos NV.

Provide EV/GP
for Galapagos NV.

Provide EV/EBITDA
for Galapagos NV.

Provide EV/EBIT
for Galapagos NV.

Provide EV/OCF
for Galapagos NV.

Provide EV/FCFF
for Galapagos NV.

Provide EV/IC
for Galapagos NV.

Show me price targets
for Galapagos NV made by professional analysts.

What are the Revenue projections
for Galapagos NV?

How accurate were the past Revenue estimates
for Galapagos NV?

What are the Net Income projections
for Galapagos NV?

How accurate were the past Net Income estimates
for Galapagos NV?

What are the EPS projections
for Galapagos NV?

How accurate were the past EPS estimates
for Galapagos NV?

What are the EBIT projections
for Galapagos NV?

How accurate were the past EBIT estimates
for Galapagos NV?

Compare the revenue forecasts
for Galapagos NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Galapagos NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Galapagos NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Galapagos NV compared to its peers.

Compare the P/E ratios
of Galapagos NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Galapagos NV with its peers.

Analyze the financial leverage
of Galapagos NV compared to its main competitors.

Show all profitability ratios
for Galapagos NV.

Provide ROE
for Galapagos NV.

Provide ROA
for Galapagos NV.

Provide ROIC
for Galapagos NV.

Provide ROCE
for Galapagos NV.

Provide Gross Margin
for Galapagos NV.

Provide Operating Margin
for Galapagos NV.

Provide Net Margin
for Galapagos NV.

Provide FCF Margin
for Galapagos NV.

Show all solvency ratios
for Galapagos NV.

Provide D/E Ratio
for Galapagos NV.

Provide D/A Ratio
for Galapagos NV.

Provide Interest Coverage Ratio
for Galapagos NV.

Provide Altman Z-Score Ratio
for Galapagos NV.

Provide Quick Ratio
for Galapagos NV.

Provide Current Ratio
for Galapagos NV.

Provide Cash Ratio
for Galapagos NV.

What is the historical Revenue growth
over the last 5 years for Galapagos NV?

What is the historical Net Income growth
over the last 5 years for Galapagos NV?

What is the current Free Cash Flow
of Galapagos NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Galapagos NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Galapagos NV

Current Assets 3.7B
Cash & Short-Term Investments 3.4B
Receivables 101.5m
Other Current Assets 133.2m
Non-Current Assets 625.2m
Long-Term Investments 51.4m
PP&E 128.5m
Intangibles 252.3m
Other Non-Current Assets 193m
Current Liabilities 364.8m
Accounts Payable 128.3m
Other Current Liabilities 236.5m
Non-Current Liabilities 1B
Long-Term Debt 6.7m
Other Non-Current Liabilities 1B
Efficiency

Earnings Waterfall
Galapagos NV

Revenue
503.8m EUR
Cost of Revenue
-306.1m EUR
Gross Profit
197.7m EUR
Operating Expenses
-411.5m EUR
Operating Income
-213.9m EUR
Other Expenses
474.4m EUR
Net Income
260.5m EUR

Free Cash Flow Analysis
Galapagos NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GLPG Profitability Score
Profitability Due Diligence

Galapagos NV's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

34/100
Profitability
Score

Galapagos NV's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

GLPG Solvency Score
Solvency Due Diligence

Galapagos NV's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
56/100
Solvency
Score

Galapagos NV's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLPG Price Targets Summary
Galapagos NV

Wall Street analysts forecast GLPG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLPG is 35.77 EUR with a low forecast of 23.74 EUR and a high forecast of 57.75 EUR.

Lowest
Price Target
23.74 EUR
8% Downside
Average
Price Target
35.77 EUR
39% Upside
Highest
Price Target
57.75 EUR
124% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GLPG?

Click here to dive deeper.

Dividends

Galapagos NV
does not pay dividends
Shareholder Yield

Current shareholder yield for GLPG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

GLPG News

Other Videos

Profile

Galapagos NV Logo
Galapagos NV

Country

Belgium

Industry

Biotechnology

Market Cap

1.7B EUR

Dividend Yield

0%

Description

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Contact

ANTWERPEN
MALINES (MECHELEN)
Generaal De Wittelaan 3
+3215342900.0
www.glpg.com

IPO

2005-05-06

Employees

1 309

Officers

CEO, Chairman, Interim Head of R&D
Dr. Paulus A. Stoffels M.D., Ph.D.
Executive VP, CFO & COO
Mr. Thad Huston
Head of Investor Relations
Ms. Sofie Van Gijsel
Executive VP & General Counsel
Ms. Valeria Cnossen
Head of Corporate Communication
Marieke Vermeersch
Executive VP & Chief Human Resources Officer
Ms. Annelies Missotten
Show More
Head of Development
Ms. Ellen Van Der Aar
Senior VP & Head of Business Development
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.
Head of Medical Affairs
Ms. Alice Dietrich
Head of Small Molecules Discovery & Senior VP
Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one GLPG stock?

The intrinsic value of one GLPG stock under the Base Case scenario is 28.46 EUR.

Is GLPG stock undervalued or overvalued?

Compared to the current market price of 25.8 EUR, Galapagos NV is Undervalued by 9%.

Back to Top